ArticleInternational journal of clinical and experimental pathology2018
Differential diagnosis between hepatocellular carcinoma and cirrhosis by serum amino acids and acylcarnitines.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Systematic review of metabolomic profiles linked to liver cancer.Journal of liver cancer · 2026Article
- Metabolic biomarkers for predicting onset and severity of CAR-T therapy-induced cytokine release syndrome in multiple myeloma.Frontiers of medicine · 2025Article
- Review
- Article
- Molecular and Metabolic Phenotyping of Hepatocellular Carcinoma for Biomarker Discovery: A Meta-Analysis.Metabolites · 2023Article
- High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.Frontiers in molecular biosciences · 2023Article
- Evaluation of Amino Acids Profile as Non-Invasive Biomarkers of Hepatocellular Carcinoma in Egyptians.Tropical medicine and infectious disease · 2022Article
- Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma.Metabolites · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The routine biochemical parameters for hepatocellular carcinoma (HCC) diagnosis are all protein markers. Serum concentrations of these markers can be affected by some benign diseases. Most of the occurrence of HCC has a background of cirrhosis, posing a great challenge to differential diagnosis of HCC from cirrhosis using traditional biochemical parameters. Values of serum small molecular metabolites for HCC diagnosis are not fully evaluated. In this study, a traditionalmass spectrometry-based screening strategy was employed to profile amino acids and acylcarnitines in blood samples collected from HCC and cirrhosis patients. Each whole blood specimen was sampled on filter paper and dried at room temperature. Metabolites in the dried blood spots were extracted using organic solvent and then concentrated for mass spectrometry analysis. It was found that 11 parameters, including amino acids, acylcarnitines and some of their relevant ratios, could be used to construct a satisfied differential diagnosis model. In this model, most of the relevant amino acids were essential amino acids. It was noticed that short-chain acylcarnitines tended to be risk factors for HCC. Long-chain acylcarnitines seemed to be risk factors for cirrhosis. This study demonstrates the value of mass spectrometry-based analysis for differential diagnosis of HCC and cirrhosis. Improved differential diagnosis ability may be achieved by combined use of traditional protein markers along with metabolite markers.
Indexed as
Identifiers
31938282PMC6958111W3027252364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.